Clinical Trial Update: Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating clofarabine, melphalan, and thiotepa followed by donor stem cell transplant for high-risk hematologic cancers shows comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Clofarabine (clofarabine)
• Melphalan (Melphalan)
• THIOTEPA (THIOTEPA)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Graft Versus Host Disease, Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-27